Northern Trust Corp Has $11.23 Million Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Northern Trust Corp boosted its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 5.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,314,871 shares of the biopharmaceutical company's stock after purchasing an additional 68,174 shares during the period. Northern Trust Corp owned approximately 0.84% of Ocular Therapeutix worth $11,229,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in OCUL. Raymond James Financial Inc. bought a new position in Ocular Therapeutix during the 4th quarter valued at $1,722,000. Charles Schwab Investment Management Inc. boosted its stake in Ocular Therapeutix by 1.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,131,485 shares of the biopharmaceutical company's stock valued at $9,663,000 after acquiring an additional 21,025 shares during the last quarter. Barclays PLC boosted its stake in Ocular Therapeutix by 37.1% during the 3rd quarter. Barclays PLC now owns 511,522 shares of the biopharmaceutical company's stock valued at $4,451,000 after acquiring an additional 138,441 shares during the last quarter. RoundAngle Advisors LLC bought a new position in Ocular Therapeutix during the 4th quarter valued at $1,695,000. Finally, Tower Research Capital LLC TRC boosted its stake in Ocular Therapeutix by 2,045.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company's stock valued at $76,000 after acquiring an additional 8,446 shares during the last quarter. 59.21% of the stock is owned by institutional investors and hedge funds.

Ocular Therapeutix Price Performance

Shares of OCUL traded down $0.08 during mid-day trading on Thursday, hitting $7.22. The company's stock had a trading volume of 1,045,016 shares, compared to its average volume of 1,398,638. The firm has a 50-day moving average price of $7.36 and a 200 day moving average price of $8.07. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of -5.47 and a beta of 1.51. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. Ocular Therapeutix, Inc. has a fifty-two week low of $4.79 and a fifty-two week high of $11.78.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last released its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.05). The firm had revenue of $17.08 million during the quarter, compared to analysts' expectations of $16.89 million. Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. On average, research analysts predict that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Royal Bank of Canada assumed coverage on shares of Ocular Therapeutix in a research report on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 price target on the stock. Needham & Company LLC reduced their price target on shares of Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. William Blair assumed coverage on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. They issued an "outperform" rating on the stock. JMP Securities set a $19.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. Finally, HC Wainwright reiterated a "buy" rating and issued a $15.00 price objective on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $16.25.

Insider Buying and Selling

In other Ocular Therapeutix news, insider Pravin Dugel sold 21,475 shares of Ocular Therapeutix stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $6.87, for a total value of $147,533.25. Following the completion of the sale, the insider now directly owns 3,520,318 shares in the company, valued at $24,184,584.66. The trade was a 0.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard L. Md Lindstrom bought 10,000 shares of Ocular Therapeutix stock in a transaction on Thursday, May 8th. The stock was acquired at an average price of $6.96 per share, with a total value of $69,600.00. Following the completion of the purchase, the director now directly owns 172,704 shares of the company's stock, valued at approximately $1,202,019.84. The trade was a 6.15% increase in their ownership of the stock. The disclosure for this purchase can be found here. 2.30% of the stock is currently owned by corporate insiders.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.